Biophage, Inc.

Home · About Us · Mission & Vision · The Science · Pipeline · Team · Contact · Investors

A dramatic, ultra-detailed close-up of a stylized bacteriophage rendered as if photographed through a high-end electron microscope, with a geometric icosahedral head and slender tail fibers attaching to a textured, rod-shaped bacterium. The color palette is deep cyan and soft teal, with selective bright accents to differentiate viral and bacterial structures. A faint grid and data overlays hover in the blurred background, hinting at genomic analysis. Subtle studio-style lighting from one side creates crisp highlights along the viral capsid edges and gentle shadows on the bacterial surface. Shot in macro, with a shallow depth of field and photographic realism, the image feels precise, modern, and scientific, ideal for explaining phage mechanisms to investors.
A dramatic, ultra-detailed close-up of a stylized bacteriophage rendered as if photographed through a high-end electron microscope, with a geometric icosahedral head and slender tail fibers attaching to a textured, rod-shaped bacterium. The color palette is deep cyan and soft teal, with selective bright accents to differentiate viral and bacterial structures. A faint grid and data overlays hover in the blurred background, hinting at genomic analysis. Subtle studio-style lighting from one side creates crisp highlights along the viral capsid edges and gentle shadows on the bacterial surface. Shot in macro, with a shallow depth of field and photographic realism, the image feels precise, modern, and scientific, ideal for explaining phage mechanisms to investors.
A dramatic, ultra-detailed close-up of a stylized bacteriophage rendered as if photographed through a high-end electron microscope, with a geometric icosahedral head and slender tail fibers attaching to a textured, rod-shaped bacterium. The color palette is deep cyan and soft teal, with selective bright accents to differentiate viral and bacterial structures. A faint grid and data overlays hover in the blurred background, hinting at genomic analysis. Subtle studio-style lighting from one side creates crisp highlights along the viral capsid edges and gentle shadows on the bacterial surface. Shot in macro, with a shallow depth of field and photographic realism, the image feels precise, modern, and scientific, ideal for explaining phage mechanisms to investors.

Development Pipeline

Explore Biophage’s staged programs, from discovery through pivotal studies, aligned with EPA and FDA approvals.

About

Equine & Livestock Pipeline Overview

Biophage is advancing targeted bacteriophage therapies for equine, livestock, and aquaculture (farmed fish) infections, with lead programs mapping to EPA antimicrobial biopesticide routes and FDA veterinary drug pathways on an accelerated, milestone-driven development timeline.

Investor overview
A sleek stainless-steel bioreactor vessel labeled “Biophage, Inc.” standing on a spotless white lab bench, surrounded by neatly arranged glass flasks filled with pale amber bacterial cultures, each marked with livestock pathogen strain codes. In the background, refrigerated incubators and a large digital screen display a crisp, blue-toned schematic of a bacteriophage attacking bacteria. Cool, even overhead laboratory lighting reflects subtly off metal and glass, creating a professional, clinical atmosphere. Captured at eye level with photographic realism and moderate depth of field so the bioreactor and screen are in sharp focus while the distant lab equipment softens, the composition emphasizes innovation and precision in veterinary bacteriophage therapy.
A sleek stainless-steel bioreactor vessel labeled “Biophage, Inc.” standing on a spotless white lab bench, surrounded by neatly arranged glass flasks filled with pale amber bacterial cultures, each marked with livestock pathogen strain codes. In the background, refrigerated incubators and a large digital screen display a crisp, blue-toned schematic of a bacteriophage attacking bacteria. Cool, even overhead laboratory lighting reflects subtly off metal and glass, creating a professional, clinical atmosphere. Captured at eye level with photographic realism and moderate depth of field so the bioreactor and screen are in sharp focus while the distant lab equipment softens, the composition emphasizes innovation and precision in veterinary bacteriophage therapy.
A sleek stainless-steel bioreactor vessel labeled “Biophage, Inc.” standing on a spotless white lab bench, surrounded by neatly arranged glass flasks filled with pale amber bacterial cultures, each marked with livestock pathogen strain codes. In the background, refrigerated incubators and a large digital screen display a crisp, blue-toned schematic of a bacteriophage attacking bacteria. Cool, even overhead laboratory lighting reflects subtly off metal and glass, creating a professional, clinical atmosphere. Captured at eye level with photographic realism and moderate depth of field so the bioreactor and screen are in sharp focus while the distant lab equipment softens, the composition emphasizes innovation and precision in veterinary bacteriophage therapy.
A meticulously organized regulatory strategy workspace, featuring a large, matte-white desk with a slim laptop displaying an EPA and FDA submission dashboard filled with clean charts and timelines. Beside it lie neatly stacked briefing binders labeled “EPA Biopesticide Dossier” and “FDA Veterinary Biologic,” along with color-coded sticky-note tabs and a polished steel pen. In the background, a glass wall reveals frosted icons of bacteriophages and livestock silhouettes. Soft, diffused daylight from a nearby window mixes with cool overhead office lighting, eliminating harsh shadows and creating a calm, focused atmosphere. Shot from a slightly elevated angle in photographic realism with sharp focus throughout, the composition communicates investor-ready regulatory planning and disciplined biotech operations.
A meticulously organized regulatory strategy workspace, featuring a large, matte-white desk with a slim laptop displaying an EPA and FDA submission dashboard filled with clean charts and timelines. Beside it lie neatly stacked briefing binders labeled “EPA Biopesticide Dossier” and “FDA Veterinary Biologic,” along with color-coded sticky-note tabs and a polished steel pen. In the background, a glass wall reveals frosted icons of bacteriophages and livestock silhouettes. Soft, diffused daylight from a nearby window mixes with cool overhead office lighting, eliminating harsh shadows and creating a calm, focused atmosphere. Shot from a slightly elevated angle in photographic realism with sharp focus throughout, the composition communicates investor-ready regulatory planning and disciplined biotech operations.
A meticulously organized regulatory strategy workspace, featuring a large, matte-white desk with a slim laptop displaying an EPA and FDA submission dashboard filled with clean charts and timelines. Beside it lie neatly stacked briefing binders labeled “EPA Biopesticide Dossier” and “FDA Veterinary Biologic,” along with color-coded sticky-note tabs and a polished steel pen. In the background, a glass wall reveals frosted icons of bacteriophages and livestock silhouettes. Soft, diffused daylight from a nearby window mixes with cool overhead office lighting, eliminating harsh shadows and creating a calm, focused atmosphere. Shot from a slightly elevated angle in photographic realism with sharp focus throughout, the composition communicates investor-ready regulatory planning and disciplined biotech operations.

Program, Pathogen, Market Snapshot

Review detailed tables of each program’s indication, target pathogens, formulation approach, regulatory track, and estimated launch window to quickly compare commercial and technical priorities across Biophage’s equine and livestock portfolios.

ProgramTarget PathogenIndicationRegulatory TrackStage
BX-101 (lead)Streptococcus equiStrangles in horsesEPA / FDA (veterinary biologic)Testing
BX-201Streptococcus zooepidemicusRespiratory & wound infections in horsesFDA (veterinary)Discovery
BX-301Rhodococcus equiFoal pneumoniaFDA (veterinary)Target evaluation
BX-401Aeromonas spp. / Streptococcus iniaeBacterial disease in farmed fish (aquaculture)EPA / FDA (aquaculture)Discovery
BX-501Salmonella spp.Enteric disease & food-safety in cattle and swineEPA biopesticideTarget evaluation
Illustrative development pipeline across equine, livestock, and aquaculture. Programs and timelines are targets and subject to change as data matures.
Request full data
Next: Team →
Next: Team →
Next: Team →